CMRR
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT03122925
OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA).
HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label incorporation from glucose to glutamate in the brain using in vivo magnetic resonance spectroscopy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Minneapolis, Minnesota, 55455, United States
The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA patients and in a group of age-matched healthy controls using 13C MRS in vivo together with systemic i.v. infusion of 13C-labeled glucose.
The investigators aim to obtain adequate data in 16 subjects grouped as follows:
In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case some subjects withdraw before completion of the MR scan, or in case the measured data are not adequate (e.g. technical problem with the scanner).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Control subjects:
MR
Time frame: Baseline
value between 0 to 2 micromol/g/min
University of Minnesota
Other
Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04346238
Brain Diseases, Central Nervous System Diseases
Montpellier, France
View Trial DetailsNCT04921930
Brain Diseases, Central Nervous System Diseases
Paris, France
View Trial DetailsNCT04577352
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial DetailsNCT02255435
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial Details